

IN THE CLAIMS:

Please rewrite claim 1 to read as follows:

1. (Currently Amended) A method of reducing one or more deleterious side effects of radiation treatment in a subject undergoing radiation treatment, the side effects being one or more of those selected from the group consisting of acute mucosal effects on the urinary or gastrointestinal tract, fatigue, diarrhea, rectal bleeding, proctitis, sigmoiditis, urinary frequency, prostatitis, cystitis, dermatitis, ~~pneumonitis~~, large bowel irritation, small bowel irritation, nausea and vomiting, comprising administering to said subject a side-effect reducing amount of a selective cyclooxygenase-2.

B 2. (Original) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is rofecoxib. C

3. (Original) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is celecoxib.

4. (Original) The method of claim 1, wherein the reduced side effect comprises an acute mucosal effect of radiation on the urinary or gastrointestinal tract.

5. (Original) The method of claim 1, wherein the side effect reduced comprises fatigue.

6. (Original) The method of claim 1, wherein the reduced side effect comprises a disorder selected from the group consisting of diarrhea, rectal bleeding, proctitis, and sigmoiditis.

7. (Original) The method of claim 1, wherein the reduced side effect comprises urinary frequency, prostatitis, or cystitis.

8. (Original) The method of claim 1, wherein the radiation treatment is directed outside the pelvis.

B' cont
9. (Original) The method of claim 1, wherein the reduced side effect comprises dermatitis.

10. (Original) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is administered orally, topically, parenterally, or by inhalation spray.

11. (Original) The method of claim 1, wherein the cyclooxygenase-2 inhibitors is administered as a tablet, troche, lozenge, aqueous or oily suspension, dispersible powder or granule, emulsion; hard or soft capsule, syrup or elixer.

12. (Original) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is administered in a dosage amount of about 0.01 to 200 mg/kg of body weight of the subject.